FDA will allow email ‘clarifications’ after pharma company meetingsnews2025-11-20T14:34:56+00:00November 20th, 2025|Endpoints News|
Flagship and portfolio companies do deals with GSK, Merck KGaA and Saudi Arabianews2025-11-20T14:27:08+00:00November 20th, 2025|Endpoints News|
FDA approves new indication and monthly dose of Regeneron’s Eylea HDnews2025-11-20T14:14:22+00:00November 20th, 2025|Endpoints News|
Aspen gets $115M for Parkinson’s cell therapy, potential IPO in sight next yearnews2025-11-20T12:02:48+00:00November 20th, 2025|Endpoints News|
Post-Hoc Live: The drug industry’s Mr. Reality Check, Derek Lowenews2025-11-20T12:00:14+00:00November 20th, 2025|Endpoints News|
Novartis raises the sales bar for key cancer drugs, tweaks yearly growth guidancenews2025-11-20T11:43:02+00:00November 20th, 2025|Endpoints News|
Innovent to seek China approval of high-dose obesity shot after Phase 3 hitnews2025-11-20T11:30:31+00:00November 20th, 2025|Endpoints News|
Ensoma halves workforce as genetic medicines startup enters clinicnews2025-11-19T20:52:55+00:00November 19th, 2025|Endpoints News|
PBMs, FTC clash in court over agency’s in-house insulin challengenews2025-11-19T20:45:14+00:00November 19th, 2025|Endpoints News|
Flagship’s Tessera to start first human trial using new gene writing platformnews2025-11-19T20:38:49+00:00November 19th, 2025|Endpoints News|
